Aptose Biosciences Future Growth
Future criteria checks 0/6
Aptose Biosciences's earnings are forecast to decline at 4.5% per annum. EPS is expected to grow by 55.9% per annum.
Key information
-4.5%
Earnings growth rate
55.9%
EPS growth rate
| Biotechs earnings growth | 41.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Jun 2024 |
Recent future growth updates
Recent updates
Here's Why We're Watching Aptose Biosciences' (TSE:APS) Cash Burn Situation
Mar 26
We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate
Dec 08We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate
Aug 05We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully
Apr 02Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth
Sep 30Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling
Feb 07
Is Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?
Jan 03We're Not Very Worried About Aptose Biosciences' (TSE:APS) Cash Burn Rate
Nov 29Jotin Marango Is The Senior VP & Chief Business Officer of Aptose Biosciences Inc. (TSE:APS) And They Just Sold 26% Of Their Shares
Jul 11Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling
Jun 27Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -51 | N/A | N/A | 2 |
| 12/31/2024 | N/A | -44 | N/A | N/A | 3 |
| 3/31/2024 | N/A | -47 | -45 | -45 | N/A |
| 12/31/2023 | N/A | -51 | -45 | -45 | N/A |
| 9/30/2023 | N/A | -49 | -44 | -44 | N/A |
| 6/30/2023 | N/A | -48 | -40 | -40 | N/A |
| 3/31/2023 | N/A | -44 | -34 | -34 | N/A |
| 12/31/2022 | N/A | -42 | -32 | -32 | N/A |
| 9/30/2022 | N/A | -56 | -40 | -40 | N/A |
| 6/30/2022 | N/A | -58 | -41 | -41 | N/A |
| 3/31/2022 | N/A | -61 | -43 | -43 | N/A |
| 12/31/2021 | N/A | -65 | -44 | -43 | N/A |
| 9/30/2021 | N/A | -56 | -38 | -38 | N/A |
| 6/30/2021 | N/A | -58 | -38 | -38 | N/A |
| 3/31/2021 | N/A | -60 | -36 | -36 | N/A |
| 12/31/2020 | N/A | -55 | -34 | -34 | N/A |
| 9/30/2020 | N/A | -48 | -30 | -30 | N/A |
| 6/30/2020 | N/A | -42 | -27 | -27 | N/A |
| 3/31/2020 | N/A | -32 | -25 | -25 | N/A |
| 12/31/2019 | N/A | -26 | -22 | -22 | N/A |
| 9/30/2019 | N/A | -25 | -21 | -21 | N/A |
| 6/30/2019 | N/A | -24 | -20 | -20 | N/A |
| 3/31/2019 | N/A | -28 | -24 | -24 | N/A |
| 12/31/2018 | N/A | -29 | -24 | -23 | N/A |
| 9/30/2018 | N/A | -26 | -21 | -21 | N/A |
| 6/30/2018 | N/A | -23 | -18 | -18 | N/A |
| 3/31/2018 | N/A | -15 | -12 | -12 | N/A |
| 12/31/2017 | N/A | -12 | N/A | -10 | N/A |
| 9/30/2017 | N/A | -11 | N/A | -10 | N/A |
| 6/30/2017 | N/A | -12 | N/A | -11 | N/A |
| 3/31/2017 | N/A | -14 | N/A | -12 | N/A |
| 12/31/2016 | N/A | -14 | N/A | -12 | N/A |
| 9/30/2016 | N/A | -15 | N/A | -12 | N/A |
| 6/30/2016 | N/A | -14 | N/A | -12 | N/A |
| 3/31/2016 | N/A | -12 | N/A | -12 | N/A |
| 1/1/2016 | N/A | -12 | N/A | -10 | N/A |
| 9/30/2015 | N/A | -9 | N/A | -8 | N/A |
| 12/31/2014 | N/A | -12 | N/A | -10 | N/A |
| 5/31/2014 | N/A | -10 | N/A | -8 | N/A |
| 2/28/2014 | N/A | -7 | N/A | -5 | N/A |
| 11/30/2013 | N/A | -6 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if APS's revenue is forecast to grow faster than the Canadian market.
High Growth Revenue: APS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if APS's Return on Equity is forecast to be high in 3 years time